MGI stays at market perform rating from JMP

MGI Pharma, Inc. was reiterated at market perform by JMP Securities analyst Charles C. Duncan after the company released its first-quarter 2006 financials, which were in line with expectations on top and bottom lines. Aloxi missed sales estimates. JMP lowered its Aloxi sales estimates. Shares of the Bloomington, Minn., biopharmaceutical company were up 23 cents, or 1.31%, at $17.84 on volume of 1,663,367 shares versus the three-month running average of 969,779 shares. (Nasdaq: MOGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.